article thumbnail

New Phase 3 Data Show TAK-620 (maribavir), an Investigational Drug for the Treatment of Transplant Recipients with Refractory/Resistant Cytomegalovirus (CMV) Infections, Meets Primary Endpoint

The Pharma Data

Maribavir, an orally bioavailable anti-CMV compound, is the only antiviral agent presently in Phase 3 development for the treatment of post-transplant patients with CMV in SOT or HSCT. In transplant recipients, reactivation of CMV can lead to serious consequences including loss of the transplanted organ and, in extreme cases, can be fatal.

Drugs 52
article thumbnail

The impact of AI and ML on the future of drug discovery  

Drug Discovery World

It contains structure-related data for more than 3 million compounds, over 5000 unique animal and human validation datasets, and physiological parameters of 196 different subject populations (different species, gender, strain, sub-strain) and counting.

Drugs 111
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Warrior's Secret

The Pharma Data

Contains a unique “living chemistry” that was poorly understood until recently…. My name is Bill Radcliffe… and I’m a data engineer and an amateur health researcher…. As a data engineer, I’m a naturally curious guy so that’s what kicked off my “career” as a health researcher…. Because the next ingredient contains….

article thumbnail

Mitigating the risks of cross-contamination during Oral Solid Dose (OSD) manufacturing

Pharmaceutical Technology

Additionally, OSD manufacturing approaches are well developed, with processes that ensure a repeatable distribution of ingredients, uniformity in dissolution, and bioavailability, which verify that the drug product is safe and effective.